Similar articles for PMID: 19485909

Year	Number of Results
1994	1
1998	1
2000	2
2002	2
2003	4
2004	5
2005	7
2006	6
2007	7
2008	6
2009	6
2010	13
2011	12
2012	10
2013	4
2014	9
2015	8
2016	8
2017	6
2018	7
2019	9
2020	7
2021	9
2022	7
2024	0

1

Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis.

Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Cugno M, et al. Curr Vasc Pharmacol. 2010 Mar;8(2):285-92. doi: 10.2174/157016110790886965. Curr Vasc Pharmacol. 2010. PMID: 19485909 Review.

2

What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Dixon WG, Symmons DP. Dixon WG, et al. Ann Rheum Dis. 2007 Sep;66(9):1132-6. doi: 10.1136/ard.2006.063867. Epub 2007 Jan 24. Ann Rheum Dis. 2007. PMID: 17251223 Free PMC article. Review.

3

Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.

Chighizola C, Schioppo T, Ingegnoli F, Meroni PL. Chighizola C, et al. Curr Vasc Pharmacol. 2012 Sep;10(5):639-46. doi: 10.2174/157016112801784503. Curr Vasc Pharmacol. 2012. PMID: 22272912 Review.

4

Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.

Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Ingegnoli F, et al. Clin Exp Rheumatol. 2010 Mar-Apr;28(2):254-7. Epub 2010 May 13. Clin Exp Rheumatol. 2010. PMID: 20483049 Clinical Trial.

5

Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.

Avouac J, Allanore Y. Avouac J, et al. Expert Opin Pharmacother. 2008 May;9(7):1121-8. doi: 10.1517/14656566.9.7.1121. Expert Opin Pharmacother. 2008. PMID: 18422470 Review.

6

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.

Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P. Popa C, et al. Ann Rheum Dis. 2005 Feb;64(2):303-5. doi: 10.1136/ard.2004.023119. Epub 2004 Jul 1. Ann Rheum Dis. 2005. PMID: 15231512 Free PMC article. Clinical Trial.

7

Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.

Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R. Tocci G, et al. Expert Opin Drug Saf. 2016 Dec;15(sup1):55-61. doi: 10.1080/14740338.2016.1218469. Expert Opin Drug Saf. 2016. PMID: 27924645 Review.

8

Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.

Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G. Cacciapaglia F, et al. Drug Dev Res. 2014 Nov;75 Suppl 1:S77-80. doi: 10.1002/ddr.21203. Drug Dev Res. 2014. PMID: 25381986 Clinical Trial.

9

Cardiovascular risk in rheumatoid arthritis: how to lower the risk?

van Breukelen-van der Stoep DF, Klop B, van Zeben D, Hazes JM, Castro Cabezas M. van Breukelen-van der Stoep DF, et al. Atherosclerosis. 2013 Nov;231(1):163-72. doi: 10.1016/j.atherosclerosis.2013.09.006. Epub 2013 Sep 20. Atherosclerosis. 2013. PMID: 24125429 Review.

10

Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.

Meroni PL, Valesini G. Meroni PL, et al. BioDrugs. 2014 Apr;28 Suppl 1:S5-13. doi: 10.1007/s40259-013-0063-0. BioDrugs. 2014. PMID: 24687234 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

136 results

Results by year